FDA Signs Off Chemomab's Lead Candidate Mid-Stage Study In Bile Duct Disease

The FDA has cleared Chemomab Therapeutics Ltd's CMMB Investigational New Drug (IND) application for CM-101 for the rare disease primary sclerosing cholangitis (PSC). CM-101, a first-in-class CCL24-neutralizing antibody, is Chemomab's lead clinical candidate.

  • The Phase 2 SPRING trial assessing CM-101 as a potential treatment for PSC is already underway in Europe and Israel and is now being expanded to include U.S. sites.
  • The SPRING trial is designed to evaluate the safety and efficacy of CM-101 over 15 weeks of treatment in patients with PSC.
  • The initial clinical readout is expected in 2022.
  • CM-101 appeared safe and well-tolerated in Phase 1a and 1b clinical studies in healthy volunteers and non-alcoholic fatty liver disease (NAFLD) patients. 
  • Primary sclerosing cholangitis is a rare and severe disease of the bile ducts in the liver. 
  • See here Benzinga's Full FDA Calendar.
  • Price Action: CMMB shares are up 14.90% at $9.69 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareFDAMoversTrading IdeasGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!